Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Lupin and its alliance partner Natco Pharma (Natco) today announced the approval from the United States Food and Drug Administration (U.S. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is the bioequivalent to the reference listed drug (RLD) Halaven® Injection of Eisai, Inc.
Eribulin Mesylate Injection is indicated for the treatment of adults with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease and unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
Lupin today announced that it has been featured for the first time in the Dow Jones Best-in-Class (DJBIC) Indices, underscoring the company's strong commitment to sustainable, responsible, and ethical business practices. Lupin has been listed in both the DJBIC World Index and the DJBIC Emerging Markets Index.
The DJBIC World Index ranks top-performing companies globally by strong ESG performance, while the DJBIC Emerging Markets Index highlights sustainability leaders across emerging economies. Lupin was previously ranked among the top 1% globally in the S&P Global Corporate Sustainability Assessment (CSA) 2025, achieving an industry-leading score of 91/100.
The Dow Jones Best-in-Class Indices recognize companies that demonstrate exceptional performance across key Environmental, Social, and Governance (ESG) parameters, based on leading S&P Global CSA scores. Inclusion in these prestigious indices reinforces Lupin's credibility with global investors, strengthens its competitive positioning, and places the company among a distinguished group of global leaders recognized for best-in-class sustainability performance.
For the full year,net profit rose 62.51% to Rs 5332.84 crore in the year ended March 2026 as against Rs 3281.62 crore during the previous year ended March 2025. Sales rose 23.86% to Rs 27487.54 crore in the year ended March 2026 as against Rs 22192.11 crore during the previous year ended March 2025.
Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25. It increased 4.1% sequentially from Rs 7100.5 crore in Q3 FY26.
Gross profit excluding other operating income stood at Rs 5,540.30 crore in Q4 FY26, up 42.90% from Rs 3,876 crore in the year-ago quarter. Gross margin expanded to 75% from 69.7% in Q4 FY25 and 73.5% in Q3 FY26.
Profit before tax stood at Rs 1,928 crore in Q4 FY26, up 115.22% from Rs 895.80 crore in Q4 FY25 and higher by 26.68% from Rs 1,522 crore in Q3 FY26.
EBITDA stood at Rs 2,626.30 crore in Q4 FY26, up 90.57% from Rs 1,378.10 crore in Q4 FY25 and higher by 10.51% from Rs 2,376.60 crore in Q3 FY26. EBITDA margin expanded 1,070 bps YoY to 35.5% from 24.8% and improved 200 bps sequentially from 33.5% in Q3 FY26.
Geographically, the U.S. market remained the largest contributor to sales during Q4 FY26, with revenue rising 56.90% YoY to Rs 3,398.70 crore. India sales increased 11.51% to Rs 1,908.20 crore, while emerging markets revenue climbed 49.21% to Rs 990.60 crore. Revenue from other developed markets rose 7.15% to Rs 845.30 crore.
Total formulations sales grew 34% YoY to Rs 7,142.80 crore, while API revenue increased 7.60% to Rs 249.10 crore. Total product sales rose 32.90% to Rs 7,391.90 crore in Q4 FY26.
Material cost increased 9.81% YoY to Rs 1,851.60 crore, while employee cost rose 24.11% to Rs 1,242.70 crore. Manufacturing and other expenses climbed 30.91% to Rs 2,209.30 crore. Finance cost rose 34.90% YoY to Rs 120.20 crore, while depreciation, amortization and impairment expense increased 13.63% to Rs 446.80 crore.
Other income surged 146.84% YoY to Rs 140.70 crore during the quarter. Forex gain stood at Rs 314.50 crore against a forex gain of Rs 29.10 crore in Q4 FY25.
Exceptional items for Q4 FY26 stood at Rs 131.30 crore compared with nil in the corresponding quarter last year.
Investment in research and development for the quarter stood at Rs 589.80 crore, equivalent to 8.0% of sales.
Operating working capital stood at Rs 7,132.40 crore as of quarter-end, while operating days stood at 87 days.
Capital expenditure for Q4 FY26 stood at Rs 305.20 crore. For the full year, capex stood at Rs 1,061.80 crore.
The company reported net debt of negative Rs 4,635.80 crore as of 31 March 2026. Net debt-to-equity ratio stood at negative 0.21, indicating a net cash position.
For the full year ended 31 March 2026, net sales increased 23.9% to Rs 27487.50 crore from Rs 22192.10 crore in FY25. Profit before tax rose 71.17% to Rs 6,872.60 crore from Rs 4,015 crore in FY25, while profit after tax increased 61.98% to Rs 5,355.50 crore from Rs 3,306.30 crore.
Full-year EBITDA jumped 68.64% to Rs 9,240.50 crore from Rs 5,479.20 crore. EBITDA margin expanded 890 bps to 33.6% from 24.7%.
Net cash from operating activities surged to Rs 7,334.50 crore in FY26 from Rs 2,999.94 crore in FY25.
Managing director Nilesh Gupta said the company’s Q4 and FY26 performance reflected strong sales growth and margin expansion in the U.S. and India markets, supported by investments in technology, execution and operational efficiencies.
Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapeutic segments.
Shares of Lupin fell 3.51% to Rs 2373.50 on the BSE.
The product is bioequivalent to Ravicti Oral Liquid (1.1 g/mL) of Horizon Therapeutics and is indicated for chronic management of patients with urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
As per IQVIA MAT December 2025, the reference listed drug Ravicti had sales of $337 million for the year ended December 2025.
Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.
The counter shed 0.33% to trade at Rs 2,343.20 on the BSE.
Dapagliflozin and Metformin Hydrochloride is a combination medication used to improve glycemic control in adults with type 2 diabetes
The counter shed 0.10% to end at Rs 2,309.45 on the BSE.